▲ Peaking
Business
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Merck and Daiichi Sankyo have withdrawn their FDA application for a lung cancer therapy following regulatory pushback, impacting a $4 billion partnership.